Company Profiles

The following are companies engaged in addressing challenges related to the Coronavirus. 

Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus, and tuberculosis.  visit

Co-Diagnostics offers a range of products and services to suit the needs of diagnostics laboratories, research institutions, and enterprises across the globe that rely on PCR technology. Co-Diagnostics was founded with a simple but ambitious goal: to bring high-quality molecular diagnostics for infectious diseases to areas and populations of the world that need them most. Since that time, Co-Diagnostics researchers have developed additional applications far beyond the detection of infectious diseases.

Mesa Biotech molecular diagnostic tests diagnostic performance of nucleic acid PCR amplification provide laboratory-quality results at the point-of-care with greater sensitivity and specificity than current infectious disease rapid immunoassay tests.  This approach brings DNA and RNA testing to a much larger population segment than is currently available.

Sonnet Biotherapeutics is a publicly traded company listed on NASDAQ (SONN:NASDAQ) that has developed a unique, new and timely platform for the delivery of an enormous number of biologic drug applications for nearly any indication. Their Fully Human Albumin Binding (FHAB) platform technology leverages a single chain antibody fragment (scFV) coupled with two flexible linker peptides that are capable of attaching to nearly any type of biologic or small molecule therapeutic.  The technology has applications in oncology and for Covid – 19.


Share This